Preferred Name | Tretinoin | |
Synonyms |
|
|
Definitions |
A naturally-occurring acid of retinol. Tretinoin binds to and activates retinoic acid receptors (RARs), thereby inducing changes in gene expression that lead to cell differentiation, decreased cell proliferation, and inhibition of tumorigenesis. This agent also inhibits telomerase, resulting in telomere shortening and eventual apoptosis of some tumor cell types. The oral form of tretinoin has teratogenic and embryotoxic properties. |
|
ID |
http://purl.obolibrary.org/obo/NCIT_C900 |
|
Accepted_Therapeutic_Use_For |
(Topical) acne vulgaris; other dermatologic conditions; some skin cancers (Oral) Acute promyelocytic leukemia (APL), characterized by the t(15;17) translocation or the PML/RARa gene refractory to or have relapsed from anthracycline chemotherapy, or for where anthracycline-based chemotherapy is contraindicated |
|
ALT_DEFINITION |
A nutrient that that body needs in small amounts to function and stay healthy. All-trans retinoic acid is made in the body from vitamin A and helps cells to grow and develop, especially in the embryo. A form of all-trans retinoic acid made in the laboratory is put on the skin to treat conditions such as acne and is taken by mouth to treat acute promyelocytic leukemia (a fast-growing cancer in which there are too many immature blood-forming cells in the blood and bone marrow). All-trans retinoic acid is being studied in the prevention and treatment of other types of cancer. |
|
CAS_Registry |
302-79-4 |
|
CHEBI_ID |
CHEBI:15367 |
|
Chemical_Formula |
C20H28O2 |
|
code |
C900 |
|
Contributing_Source |
CTRP FDA PCDC |
|
definition |
A naturally-occurring acid of retinol. Tretinoin binds to and activates retinoic acid receptors (RARs), thereby inducing changes in gene expression that lead to cell differentiation, decreased cell proliferation, and inhibition of tumorigenesis. This agent also inhibits telomerase, resulting in telomere shortening and eventual apoptosis of some tumor cell types. The oral form of tretinoin has teratogenic and embryotoxic properties. |
|
Display_Name |
Tretinoin |
|
FDA_UNII_Code |
5688UTC01R |
|
Has_Target | ||
in_subset |
http://purl.obolibrary.org/obo/NCIT_C63923 http://purl.obolibrary.org/obo/NCIT_C173383 http://purl.obolibrary.org/obo/NCIT_C173381 http://purl.obolibrary.org/obo/NCIT_C177537 http://purl.obolibrary.org/obo/NCIT_C174019 http://purl.obolibrary.org/obo/NCIT_C176424 http://purl.obolibrary.org/obo/NCIT_C116977 http://purl.obolibrary.org/obo/NCIT_C116978 http://purl.obolibrary.org/obo/NCIT_C128784 http://purl.obolibrary.org/obo/NCIT_C157711 |
|
Is_PCDC_AML_Permissible_Value_For_Variable | ||
Is_Value_For_GDC_Property | ||
label |
Tretinoin |
|
Legacy Concept Name |
Vitamin_A_Acid |
|
Maps_To |
Tretinoin |
|
NCI_Drug_Dictionary_ID |
41258 |
|
NSC Number |
122758 |
|
PDQ_Closed_Trial_Search_ID |
41258 |
|
PDQ_Open_Trial_Search_ID |
41258 |
|
Preferred_Name |
Tretinoin |
|
prefixIRI |
NCIT:C900 |
|
prefLabel |
Tretinoin |
|
Semantic_Type |
Organic Chemical Pharmacologic Substance |
|
UMLS_CUI |
C0040845 |
|
subClassOf |